Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.74 |
| ▸ | LTA4H | P09960 | 6/20 | 0.61 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.61 |
| ▸ | BAX | Q07812 | 1/20 | 0.61 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.48 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL249169 | 0.86 | ESR2 (1.00) | ESR1MEN1KMT2AESR2LTA4H | |
| SCHEMBL351854 | 0.86 | SOS1 (0.58) | ESR1MEN1KMT2AESR2LTA4H | |
| SCHEMBL6290683 | 0.86 | SOS1 (0.58) | ESR1MEN1KMT2AESR2LTA4H | |
| SCHEMBL18198 | 0.86 | ESR2 (1.00) | ESR1MEN1KMT2AESR2LTA4H | |
| SCHEMBL3175106 | 0.86 | ESR2 (1.00) | ESR1MEN1KMT2AESR2LTA4H | |
| SCHEMBL6289867 | 0.86 | SOS1 (0.58) | ESR1MEN1KMT2AESR2LTA4H | |
| SCHEMBL7811939 | 0.86 | ESR2 (1.00) | ESR1MEN1KMT2AESR2LTA4H | |
| SCHEMBL16607615 | 0.85 | MAPT (0.58) | ESR1MEN1KMT2AESR2LTA4H | |
| SCHEMBL2188901 | 0.85 | PARP10 (0.58) | ESR1MEN1KMT2AESR2LTA4H | |
| SCHEMBL4046325 | 0.83 | ESR1 (0.64) | ESR1MEN1KMT2AESR2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2020-05-12 | — | — | US | claimed |
| CN-106554382-B | Application in nucleoside phosphoramidite class compound and preparation method thereof and drug | 四川科伦博泰生物医药股份有限公司 | 2019-12-03 | — | — | CN | claimed |
| US-20190240213-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2019-08-08 | — | — | US | claimed |
| US-10092558-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2018-10-09 | — | — | US | claimed |
| US-20170035747-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2017-02-09 | — | — | US | claimed |
| US-20160317523-A1 | Treatment of Retinopathy of Prematurity (ROP) | THE CLEVELAND CLINIC FOUNDATION | 2016-11-03 | — | — | US | claimed |
| WO-2015095757-A1 | TREATMENT OF RETINOPATHY OF PREMATURITY (ROP) | THE CLEVELAND CLINIC FOUNDATION (US) | 2015-06-25 | — | — | WO | claimed |
| CN-102977015-B | Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin | FIBROGEN INC | 2015-05-06 | — | — | CN | claimed |
| US-8916585-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2014-12-23 | — | — | US | claimed |
| US-20130178417-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2013-07-11 | — | — | US | claimed |
| US-20070185159-A1 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | FIBROGEN, INC. | 2007-08-09 | — | — | US | claimed |
| US-20070155784-A1 | Novel nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. | 2007-07-05 | — | — | US | claimed |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. | 2006-09-28 | — | — | US | claimed |
| CN-1816527-A | Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin | FIBROGEN INC (US) | 2006-08-09 | — | — | CN | claimed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | claimed |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | claimed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | claimed |
| US-5082930-A | Diagnosis, tumors | MALLINCKRODT MEDICAL, INC. (US) | 1992-01-21 | — | — | US | claimed |
| EP-0247866-B1 | COUPLING AGENTS FOR RADIOLABELING PROTEINS | Mallinckrodt, Inc. (a Delaware corporation) (US) | 1990-11-14 | — | — | EP | claimed |
| EP-0395578-A2 | Acylated carbamic acid esters | CIBA-GEIGY AG (CH) | 1990-10-31 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178417-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | ESR1 3804/4885MEN1 4467/4885KMT2A 2350/4885 |
| US-20170035747-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | ESR1 3804/4885MEN1 4467/4885KMT2A 2350/4885 |
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | ESR1 2987/4885MEN1 4223/4885KMT2A 2002/4885 |
| US-20190240213-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | ESR1 3804/4885MEN1 4467/4885KMT2A 2350/4885 |
| US-10092558-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | ESR1 2987/4885MEN1 4223/4885KMT2A 2002/4885 |
| US-20070155784-A1 | Novel nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, EGLN3, EGLN2 | ESR1 3804/4885MEN1 4467/4885KMT2A 2350/4885 |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | EPOR, HIF1AN, HIF1A | ESR1 3253/4885MEN1 2544/4885KMT2A 2951/4885 |
| US-20160317523-A1 | Treatment of Retinopathy of Prematurity (ROP) | VEGFA, ALDH1A2, PGF | ESR1 4764/4885MEN1 4876/4885KMT2A 2910/4885 |
| US-20070185159-A1 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | HIF1AN, HIF1A, EPOR | ESR1 2238/4885MEN1 4703/4885KMT2A 1339/4885 |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | EPOR, HIF1AN, HIF1A | ESR1 2866/4885MEN1 2815/4885KMT2A 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.